Physician profile
Robert K Moore
NPI 1477557221
$2,002.37
in general payments reported to CMS, 2019-2025
27 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $149 · 2021: $230 · 2022: $192 · 2023: $621 · 2024: $327 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $322.00 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $277.02 | 2019-2025 | |
| Corium, LLC | $195.29 | 2022-2024 | Azstarys |
| Tris Pharma INC | $146.29 | 2020-2024 | Dyanavel Xr |
| Sobi, INC | $138.26 | 2019-2024 | |
| Kaleo, INC. | $117.36 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $116.03 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Ultragenyx Pharmaceutical INC. | $108.88 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $83.48 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $52.10 | 2019 | |
| Alk-Abello, INC | $50.98 | 2023 | Ragwitek, Odactra, Grastek |
| Nestle Healthcare Nutrition INC. | $42.66 | 2021 | |
| Mylan Pharmaceuticals INC. | $42.37 | 2019-2021 | |
| Seqirus USA INC | $35.33 | 2023 | Flucelvax Quadrivalent |
| Astrazeneca Pharmaceuticals LP | $30.35 | 2023 | Flumist Quadrivalent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $29.34 | 2024 | Sucraid |
| Rhodes Pharmaceuticals L.P. | $28.89 | 2019 | |
| Abbvie INC. | $24.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.78 | 2019 | |
| Acadia Pharmaceuticals INC | $19.89 | 2024 | Daybue |
| Verrica Pharmaceuticals INC. | $19.49 | 2025 | Ycanth |
| Biomarin Pharmaceutical INC. | $19.45 | 2025 | Voxzogo 1.2mg |
| Shire North American Group INC | $18.29 | 2019 | |
| Cranial Technologies, INC | $16.93 | 2025 | Doc Band |
| Alexion Pharmaceuticals, INC. | $15.33 | 2022 | |
| Sanofi Pasteur INC. | $14.68 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.